Medical Care

Skip Navigation LinksHome > December 2011 - Volume 49 - Issue 12 > Identifying Better Practices for Early-stage Bladder Cancer
Medical Care:
doi: 10.1097/MLR.0b013e3182353baf
Original Articles

Identifying Better Practices for Early-stage Bladder Cancer

Hollingsworth, John Malcolm MD, MS*,†,‡; Zhang, Yun S. PhD*; Miller, David C. MD, MPH*,‡,§; Skolarus, Ted A. MD, MPH*,‡,§; Wood, David P. MD§; Lee, Cheryl T. MD§; Montie, James E. MD*,‡,§; Hollenbeck, Brent K. MD, MS*,‡,§

Collapse Box


Background: Practice guidelines for nonmuscle invasive (ie, early stage) bladder cancer are ambiguous, resulting in substantial practice variation without a clear patient benefit.

Objectives: To profile urologist practice styles and empirically derive better patterns of use for common bladder cancer services.

Research Design: Retrospective cohort.

Subjects: Elderly patients diagnosed with early-stage bladder cancer between January 1, 1992 and December 31, 2005 in Surveillance, Epidemiology, and End Results-Medicare linked data.

Measures: After identifying each patient's treating urologist, we fit multilevel models to obtain reliability-adjusted measures of the urologist's use of surveillance-associated (cytoscopy and urine cytology) and treatment-associated (intravesical therapy) services during the 2 years after diagnosis. We then used the Cox proportional hazards regression to evaluate the association between a patient's risk of bladder cancer death and his urologist's frequency of service use.

Results: Regardless of disease severity, no measurable patient benefit was associated with care delivery by a urologist residing in the highest quartile for cystoscopy or intravescial therapy use. However, maximal intensity of cytology use was associated with a lower risk of bladder cancer death for patients with high-grade stage Ta/Tis (highest vs. lowest intensity quartiles: hazard ratio, 0.73; 95% confidence interval, 0.56–0.95) and stage T1 disease (hazard ratio, 0.59; 95% confidence interval, 0.49–0.72).

Conclusions: Our analysis supports a more tailored approach to patients with early-stage bladder cancer. Further, it serves as an example for applying observational data to characterize better clinical practices in the absence of experimental studies.

© 2011 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.